MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 08-19-2022
Calliditas Therapeutics AB (publ) ROCE Ratio 2011-2026 | CALT
Annual ROCE Ratio Calliditas Therapeutics AB (publ)
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -39.6 | -27.11 | - | - | -255.17 | - | - | - | - | - | - |
All numbers in SEK currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -27.11 | -255.17 | -107.29 |
Quarterly ROCE Ratio Calliditas Therapeutics AB (publ)
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -35.4 | -35.4 | -32.64 | -47.59 | -42.19 | -27.24 | -31.91 | -21.62 | -9.33 | -4.66 | -4.66 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in SEK currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -4.66 | -47.59 | -26.6 |
ROCE Ratio of other stocks in the Drug manufacturers industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
-79.15 | - | 7.5 % | $ 6.35 M |  USA |
 |
Alimera Sciences
ALIM
|
-4.18 | - | - | $ 142 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
267.43 | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
121.85 | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
3101.1 | - | 0.86 % | $ 117 M | USA |
 |
Canopy Growth Corporation
CGC
|
-24.04 | $ 0.95 | -2.04 % | $ 102 M |  Canada |
 |
Aurora Cannabis
ACB
|
-23.09 | $ 3.29 | -0.61 % | $ 86.3 M | Canada |
 |
China Pharma Holdings
CPHI
|
-59.23 | $ 0.63 | - | $ 11 M |  China |
 |
Catalent
CTLT
|
-20.78 | - | - | $ 11.5 B | USA |
 |
Athenex
ATNX
|
1076.15 | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-57.41 | - | - | $ 2.06 B |  France |
 |
Cronos Group
CRON
|
-10.43 | $ 2.51 | -0.31 % | $ 1.31 B | Canada |
 |
DURECT Corporation
DRRX
|
-249.5 | - | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
-111.87 | $ 7.96 | -1.12 % | $ 408 M | USA |
 |
Endo International plc
ENDP
|
7.34 | - | - | $ 28.9 M |  Irlanda |
 |
Pacira BioSciences
PCRX
|
-9.43 | $ 22.63 | -0.09 % | $ 1.05 B | USA |
 |
Evoke Pharma
EVOK
|
-184.26 | - | - | $ 36.6 M | USA |
 |
HEXO Corp.
HEXO
|
-85.61 | - | 2.45 % | $ 38.1 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
-8.06 | $ 3.15 | 3.28 % | $ 44.3 M | USA |
 |
Rockwell Medical
RMTI
|
-31.33 | $ 1.05 | 2.45 % | $ 24.5 M | USA |
 |
Bausch Health Companies
BHC
|
-94.23 | $ 4.98 | -2.35 % | $ 1.82 B | Canada |
 |
Solid Biosciences
SLDB
|
-90.02 | $ 6.9 | -3.36 % | $ 604 M | USA |
 |
Sundial Growers
SNDL
|
-68.48 | $ 1.36 | - | $ 3.37 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
-84.11 | $ 2.39 | -6.13 % | $ 2.97 M | USA |
 |
Harrow Health
HROW
|
58.18 | $ 35.27 | 3.74 % | $ 1.3 B | USA |
 |
OptiNose
OPTN
|
26.27 | - | - | $ 1.08 B | USA |
 |
Tilray
TLRY
|
-41.31 | $ 6.43 | -0.31 % | $ 3.97 B | Canada |
 |
Evolus
EOLS
|
141.36 | $ 4.61 | -1.6 % | $ 297 M | USA |
 |
Veru
VERU
|
-114.23 | $ 2.3 | - | $ 310 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
34.66 | - | -39.89 % | $ 27.7 M | USA |
 |
Relmada Therapeutics
RLMD
|
-68.31 | $ 6.06 | 3.41 % | $ 239 M | USA |
 |
Viatris
VTRS
|
3.74 | $ 13.43 | 1.02 % | $ 16.1 B | USA |
 |
OrganiGram Holdings
OGI
|
-35.84 | $ 1.36 | - | $ 402 M | Canada |
 |
PetIQ
PETQ
|
5.46 | - | 1.64 % | $ 400 M | USA |
 |
PLx Pharma
PLXP
|
-114.37 | - | -27.8 % | $ 2.56 M | USA |
 |
ProPhase Labs
PRPH
|
32.97 | - | - | $ 5.07 M | USA |
 |
Jupiter Wellness
JUPW
|
-116.71 | - | - | $ 33.6 M | USA |
 |
Radius Health
RDUS
|
21.53 | - | - | $ 1.42 B | USA |
 |
Lannett Company
LCI
|
70.21 | - | 1.15 % | $ 7.11 M | USA |
 |
SCYNEXIS
SCYX
|
-32.55 | $ 0.88 | 0.79 % | $ 43.9 M | USA |
 |
TherapeuticsMD
TXMD
|
-29.1 | $ 2.35 | 1.73 % | $ 24.5 M | USA |
 |
cbdMD
YCBD
|
-235.96 | $ 0.78 | 2.25 % | $ 3.36 M | USA |
 |
Organogenesis Holdings
ORGO
|
-0.49 | $ 2.42 | -2.23 % | $ 319 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-29.88 | - | - | $ 193 M | Canada |
 |
Perrigo Company plc
PRGO
|
-14.92 | $ 9.64 | 0.68 % | $ 1.34 B | USA |
 |
Assertio Holdings
ASRT
|
-22.92 | $ 15.21 | 8.64 % | $ 97.4 M | USA |
 |
Recro Pharma
REPH
|
-6.09 | - | -4.76 % | $ 65.3 M | USA |
 |
Tricida
TCDA
|
-70162.39 | - | - | $ 3.25 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-76.25 | - | - | $ 55.5 M | USA |